We got a kinda positive mention near the bottom
(Im never getting another pzifer)
So what are you guys expecting from the upcoming earnings call? You guys gonna buy? Sell? Yolo on puts or calls?
60/70 $ x shares.....take a look
It's worth noting that the covid vaccine is not Novavax's only revenue stream. No idea how much Novavax gets for Matrix-M, but presumably it's not $0!
100-200 million doses per year, for a few bucks per dose of the R21/Matrix-M vaccine.
"The vaccine - called R21 - appears to be hugely effective, in stark contrast to previous ventures in the same field.
Ghana's drug regulators have assessed the final trial data on the vaccine's safety and effectiveness, which is not yet public, and have decided to use it.
The World Health Organization is also considering approving the vaccine.
Malaria kills about 620,000 people each year, most of them young children.
It has been a massive, century-long, scientific undertaking to develop a vaccine that protects the body from the malaria parasite.
Trial data from preliminary studies in Burkina Faso showed the R21 vaccine was up to 80% effective when given as three initial doses, and a booster a year later. "
Diamond hands, rocket ride to the moon, yo?!!!??!
I can't say I feel much sympathy here for anyone that lost big. It's not like you had a year and a half to get out or anything. New CEO BTW, totally a BK cleanup job. Company is dead as dead can be.
I can't imagine it being more than six months out. Thoughts?
Now I'm just curious how low it could possibly go
In summary, we report enhanced neutralization of Omicron BA.1 and BA.4/BA.5 following three doses of the NVX-CoV2373 vaccine with responses comparing well to three doses of an mRNA vaccine. We note that 6 months after two doses of NVX-CoV2373, increased binding antibodies were reported, suggesting that responses after the third dose may mature further10. As durability of vaccine platforms varies, future studies should assess this for NVX-CoV2373 neutralization at later time-points10. The two dose NVX-CoV2372 vaccine regimen elicits robust memory CD4+ and CD8+ T cell responses in 100% and 65% of individuals respectively7,10. In addition, the two dose regimen induces antibodies with multiple Fc-mediated functions, which in non-human primate and human cohorts likely contribute to protection from infection10. This T cell and Fc effector function data, which is unlikely to differ following a third dose of the NVX-CoV2373 vaccine, coupled with neutralizing antibodies we have described here, suggests that this vaccine is likely to prevent severe disease after SARS-CoV-2 breakthrough infection with Omicron BA.4/5 sub-lineages